A 32-year-old man with schizophrenia has been on risperidone 6 mg daily for 8 months. He presents to the outpatient clinic with his wife, who reports that he has gained 12 kg over the past 6 months. On examination, his weight is 82 kg (BMI 28.5), fasting blood glucose is 118 mg/dL, and triglycerides are 210 mg/dL. He denies polydipsia or polyuria. His mental state is stable. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Context This patient presents with **metabolic syndrome** emerging during risperidone therapy — a well-recognized adverse effect of second-generation antipsychotics (SGAs), particularly risperidone and olanzapine. The constellation of weight gain, dyslipidemia, and impaired fasting glucose mandates intervention. ## Why Switch to Aripiprazole? **Key Point:** Aripiprazole has the **lowest propensity for metabolic side effects** among SGAs. It causes minimal weight gain, does not significantly elevate glucose or lipids, and is the preferred agent when metabolic complications emerge during SGA therapy. **High-Yield:** Among SGAs, metabolic risk ranking (highest to lowest): - Olanzapine > Quetiapine > Risperidone > Paliperidone > Aripiprazole > Lurasidone Aripiprazole's unique mechanism (partial D~2~ agonist rather than full antagonist) and lower affinity for H~1~ and muscarinic receptors explain its metabolic neutrality. ## Management Algorithm ```mermaid flowchart TD A[SGA-induced metabolic syndrome]:::outcome --> B{Psychotic symptoms stable?}:::decision B -->|Yes| C[Switch to metabolically neutral SGA]:::action C --> D[Aripiprazole preferred]:::action B -->|No| E[Optimize current dose first]:::action E --> F[Then switch if needed]:::action D --> G[Counsel diet + exercise]:::action G --> H[Recheck metabolic panel in 3 months]:::outcome ``` ## Why Not the Other Options? | Option | Reason for Rejection | |--------|---------------------| | Continue risperidone + metformin | Metformin is **adjunctive**, not primary management. Switching the offending agent is superior when mental state is stable. | | Add topiramate | Off-label use; evidence is weak. Topiramate carries its own side effects (cognitive dulling, weight loss unpredictable). Not first-line. | | Reduce risperidone + add benzodiazepine | Dose reduction risks relapse in stable schizophrenia. Benzodiazepines do not treat metabolic complications and carry dependence risk. | **Clinical Pearl:** The patient's mental state is **stable** — this is the critical permissive factor for switching. In an acutely relapsing patient, metabolic management would be deferred or combined with the current agent. **Warning:** Do NOT continue a metabolically toxic agent when a safer alternative exists in a stable patient. Metabolic syndrome increases cardiovascular mortality 2–3-fold in schizophrenia. [cite:Stahl Psychopharmacology 6e Ch 5]